Novartis Ag (NVS) Revenue (2009 - 2026)
Novartis Ag (NVS) posted Revenue of $14.4 billion for Q2 2026, up 4319.63% sequentially from $326.0 million in Q1 2026, and up 2.52% YoY from $14.1 billion in Q2 2025.
Novartis Ag (NVS) Revenue (2009 - 2026) Analysis & Trends
Novartis Ag has reported Revenue for 18 years, with the latest figure at $14.4 billion in Q2 2026.
- Quarterly Revenue rose 2.52% year-over-year to $14.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.5 billion (down 69.59% YoY) and the FY2025 annual result came in at $54.5 billion, up 8.38% from the prior year.
- Revenue rose to $14.4 billion in Q2 2026 per NVS's latest filing, from $326.0 million in the prior quarter.
- Over five years, Revenue peaked at $25.3 billion in Q4 2022 and troughed at -$127.0 million in Q1 2024.
- A 5-year average of $8.2 billion and a median of $404.0 million in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2024: Revenue surged 837.5% in 2022, then slumped 139.2% in 2024.
- Over 5 years, Revenue stood at $25.3 billion in 2022, then retreated by 12.16% to $22.2 billion in 2023, then grew by 9.47% to $24.3 billion in 2024, then slumped by 98.43% to $381.0 million in 2025, then surged by 3681.63% to $14.4 billion in 2026.
- According to Business Quant data, Revenue over the past three periods registered $14.4 billion, $326.0 million, and $381.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 15.38 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.05 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 7.80 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 15.03 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 11.28 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 13.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.41 Bn |
| Mar 31, 2026 | 326.00 Mn |
| Dec 31, 2025 | 381.00 Mn |
| Sep 30, 2025 | 404.00 Mn |
| Jun 30, 2025 | 14.05 Bn |
| Mar 31, 2025 | 125.00 Mn |
| Dec 31, 2024 | 24.34 Bn |
| Jun 30, 2024 | 12.51 Bn |
| Mar 31, 2024 | -127.00 Mn |
| Dec 31, 2023 | 22.24 Bn |
| Sep 30, 2023 | 111.00 Mn |
| Jun 30, 2023 | 11.44 Bn |
| Mar 31, 2023 | 324.00 Mn |
| Dec 31, 2022 | 25.31 Bn |
| Sep 30, 2022 | 236.00 Mn |
| Jun 30, 2022 | 12.78 Bn |
| Mar 31, 2022 | 257.00 Mn |
| Dec 31, 2021 | 25.37 Bn |
| Sep 30, 2021 | -32.00 Mn |
| Jun 30, 2021 | 12.96 Bn |